Statins as potential therapeutic agents in neuroinflammatory disorders

Current Opinion in Neurology

Volumn 16, Issue 3, 2003, Pages 393-401

  Stüve, Olaf ^a   Youssef, Sawsan ^b   Steinman, Lawrence ^b   Zamvil, Scott S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Experimental autoimmune encephalomyelitis; HMG CoA reductase inhibitors; Ischemic stroke; Multiple sclerosis

Indexed keywords

ATORVASTATIN; BETA1A INTERFERON; GLATIRAMER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERFERON BETA SERINE; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 5; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MEVINOLIN; MITOXANTRONE; NITRIC OXIDE; SIMVASTATIN; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; ANTIGEN PRESENTATION; ANTIINFLAMMATORY ACTIVITY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEGENERATIVE DISEASE; DRUG MECHANISM; GENETIC TRANSCRIPTION; HUMAN; IMMUNOMODULATION; INHIBITION KINETICS; LEUKOCYTE MIGRATION; LIVER TOXICITY; MAJOR HISTOCOMPATIBILITY COMPLEX; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; PROMOTER REGION; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; PROTEIN SECRETION; RANDOMIZED CONTROLLED TRIAL; REVIEW; T LYMPHOCYTE ACTIVATION; TH2 CELL; TREATMENT OUTCOME;

ALZHEIMER DISEASE; ANIMALS; BRAIN ISCHEMIA; CENTRAL NERVOUS SYSTEM; CEREBROVASCULAR ACCIDENT; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; LEUKOCYTES; MULTIPLE SCLEROSIS; NEURODEGENERATIVE DISEASES;

EID: 0038458980     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-200306000-00021     Document Type: Review

References (99)

1. Ginsberg HN. Effects of statins on triglyceride metabolism. Am J Cardiol 1998; 81:32B-35B.
2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease, the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-1389.
3. Jukema JW, Bruschke AV, van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995; 91:2528-2540.
4. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333:1301-1307.
5. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335:1001-1009.
6. Herd JA, Ballantyne CM, Farmer JA, et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol 1997; 80:278-286.
7. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279:1615-1622.
8. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339:1349-1357.
9. Riegger G, Abletshauser C, Ludwig M, et al. The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment. Atherosclerosis 1999; 144:263-270.
10. Pitt B, Waters D, Brown WV, van Boven AJ, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med 1999; 341:70-76.
11. Black DM, Bakker-Arkema RG, Nawrocki JW. An overview of the clinical safety profile of atorvastatin (lipitor), a new HMG-CoA reductase inhibitor. Arch Intern Med 1998; 158:577-584.
12. Davidson MH. Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust. Drugs 2001; 61:197-206.
13. Gaist D, Garcia Rodriguez LA, Huerta C, et al. Are users of lipid-lowering drugs at increased risk of peripheral neuropathy? Eur J Clin Pharmacol 2001; 56:931-933.
14. Gaist D, Jeppesen U, Andersen M, et al. Statins and risk of polyneuropathy: a case-control study. Neurology 2002; 58:1333-1337.
15. Liao JK. Isoprenoids as mediators of the biological effects of statins. J Clin Invest 2002; 110:285-288. A very comprehensive review of cholesterol synthesis, including the potential significance of statins on isoprenoid intermediates and GTP-binding proteins.
16. Toledano JE, Partridge NC. Statins: not just for cholesterol? Trends Endocrinol Metab 2000; 11:255-256.
17. Bellosta S, Ferri N, Bernini F, et al. Non-lipid-related effects of statins. Ann Med 2000; 32:164-176.
18. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001; 7:687-692. In this article it was demonstrated that statins block LFA-1 mediated cell adhesion and the costimulation of lymphocytes through binding to a novel allosteric site within the integrin. These effects were unrelated ot the inhibition of HMG-CoA reductase.
19. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac trasplantation. N Engl J Med 1995; 333:621-627.
20. Stuve O, Zamvil SS. Neurologic diseases. In: Parslow TG, Stites DP, Terr AI, Imboden JB, editors. Medical Immunology, edn 10. San Francisco: McGraw-Hill; 2001:510-526.
21. Genain CP, Cannella B, Hauser SL, Raine CS. Identification of auto-antibodies associated with myelin damage in multiple sclerosis. Nat Med 1999; 5:170-175.
22. Genain CP, Nguyen MH, Letvin NL, et al. Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate. J Clin Invest 1995; 96:2966-2974.
23. Weiner HL, Hauser SL. Neuroimmunology I: Immunoregulation in neurological disease. Ann Neurol 1982; 11:437-449.
24. Ebers G, Paty DW. The major histocompatibility complex, the immune system and multiple sclerosis. Clin Neurol Neurosurg 1979; 81:69-86.
25. Zamvil SS, Soos JM, Weiner HL. Pathogenesis and treatment of central nervous system demyelinating disease. Rev Neurol (Paris) 1998; 154:573-575.
26. Pahan K, Sheikh FG, Namboodiri AM, Singh I. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest 1997; 100:2671-2679.
27. Stanislaus R, Pahan K, Singh AK, Singh I. Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin. Neurosci Lett 1999; 269:71-74.
28. Stanislaus R, Singh AK, Singh I. Lovastatin treatment decreases mononuclear cell infiltration into the CNS of Lewis rats with experimental allergic encephalomyelitis. J Neurosci Res 2001; 66:155-162. This study showed that Lovastatin induces a bias towards Th2 cytokines ex vivo.
29. Zamvil SS, Steinman L. The T lymphocyte in experimental allergic encephalomyelitis. Annu Rev Immunol 1990; 8:579-621.
30. Martin R, McFarland HF, McFarlin DE. Immunological aspects of demyelinating diseases. Annu Rev Immunol 1992; 10:153-187.
31. H1 cytokine secretion, and the inhibition of both major histocompatibility complex (MHC) class II and costimulatory signals on antigen presenting cells
32. Bajetto A, Bonavia R, Barbero S, Schettini G. Characterization of chemokines and their receptors in the central nervous system: physiopathological implications. J Neurochem 2002; 82:1311-1329.
33. Olson TS, Ley K. Chemokines and chemokine receptors in leukocyte trafficking. Am J Physiol Regul Integr Comp Physiol 2002; 283:R7-28.
34. Rezaie P, Trillo-Pazos G, Everall IP, Male DK. Expression of beta-chemokines and chemokine receptors in human fetal astrocyte and microglial co-cultures: potential role of chemokines in the developing CNS. Gila 2002; 37:64-75.
35. Columba-Cabezas S, Serafini B, Ambrosini E, et al. Induction of macrophage-derived chemokine/CCL22 expression in experimental auto-immune encephalomyelitis and cultured microgtia: implications for disease regulation. J Neuroimmunol 2002; 130:10-21.
36. Ambrosini E, Columba-Cabezas S, Serafini B, et al. Astrocytes are the major intracerebral source of macrophage inflammatory protein-3alpha/CCL20 in relapsing experimental autoimmune encephalomyelitis and in vitro. Gila 2003; 41:290-300.
37. Kennedy KJ, Strieter RM, Kunkel SL, et al. Acute and relapsing experimental autoimmune encephalomyelitis are regulated by differential expression of the CC chemokines macrophage inflammatory protein-1alpha and monocyte chemotactic protein-1. J Neuroimmunol 1998; 92:96-108.
38. Romano M, Diomede L, Sironi M, et al. Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest 2000; 80:1095-1100.
39. Lee SJ, Benveniste EN. Adhesion molecule expression and regulation on cells of the central nervous system. J Neuroimmunol 1999; 98:77-88.
40. Sobel RA, Mitchell ME, Fondren G. Intercellular adhesion molecule-1 (ICAM-1) in cellular immune reactions in the human centrat nervous system. Am J Pathol 1990; 136 (Suppl):1309-1316.
41. Washington R, Burton J, Todd RF III, et al. Expression of immunologically relevant endothelial cell activation antigens on isolated central nervous system microvessels from patients with multiple sclerosis. Ann Neurol 1994; 35:89-97.
42. Brosnan CF, Cannella B, Battistini L, Raine CS. Cytokine localization in multiple sclerosis lesions: correlation with adhesion molecule expression and reactive nitrogen species. Neurology 1995; 45:S16-S21.
43. Cannella B, Raine CS. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 1995; 37:424-435.
44. Bo L, Peterson JW, Mork S, et al. Distribution of immunogtobulin superfamily members ICAM-1, -2, -3, and the beta 2 integrin LFA-1 in multiple sclerosis lesions. J Neuropathol Exp Neurol 1996; 55:1060-1072.
45. Frohman EM, Frohman TC, Dustin ML, et al. The induction of intercellular adhesion molecule 1 (ICAM-1) expression on human fetal astrocytes by interferon-gamma, tumor necrosis factor alpha, lymphotoxin, and interleukin-1: relevance to intracerebral antigen presentation. J Neuroimmunol 1989; 23:117-124.
46. Moingeon P, Chang HC, Wallner BP, et al. CD2-mediated adhesion facilitates T lymphocyte antigen recognition function. Nature 1989; 339:312-314.
47. Kallen J, Welzenbach K, Ramage P, et al. Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I-domain. J Mol Biol 1999; 292:1-9.
48. Yong VW, Power C, Forsyth P, Edwards DR. Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2001; 2:502-511.
49. Howard L, Glynn P. Membrane-associated metalloproteinase recognized by characteristic cleavage of myelin basic protein: assay and isolation. Methods Enzymol 1995; 248:388-395.
50. Bellosta S, Via D, Canavesi M, et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 1998; 18:1671-1678.
51. Ganne F, Vasse M, Beaudeux JL, et al. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits urokinase/urokinase-receptor expression and MMP-9 secretion by peripheral blood monocytes - a possible protective mechanism against atherothrombosis. Thromb Haemost 2000; 84:680-688.
52. Mach B, Steimle V, Martinez-Soria E, Reith W. Regulation of MHC class II genes: lessons from a disease. Annu Rev Immunol 1996; 14:301-331.
53. Chang CH, Flavell RA. Class II transactivator regulates the expression of multiple genes involved in antigen presentation. J Exp Med 1995; 181:765-767.
54. Muhlethaler-Mottet A, Otten LA, Steimle V, Mach B. Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA. EMBO J 1997; 16:2851-2860.
55. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6:1399-1402. This is the first report that demonstrated an inhibition of the major histocompatibility complex class II (CIITA) transactivator by statins
56. Dustin ML, Shaw AS. Costimulation: building an immunological synapse. Science 1999; 283:649-650.
57. Grakoui A, Bromley SK, Sumen C, et al. The immunological synapse: a molecular machine controlling T cell activation. Science 1999; 285:221-227.
58. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996; 383:787-793.
59. Panitch HS, Hirsch RL, Haley AS, Johnson KP. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1987; 1:893-895.
60. Windhagen A, Nicholson LB, Weiner HL, et al. Role of Th1 and Th2 cells in neurologic disorders. Chem Immunol 1996; 63:171-186.
61. Khoury SJ, Hancock WW, Weiner HL. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4, and prostaglandin E expression in the brain. J Exp Med 1992; 176:1355-1364.
62. Begolka WS, Vandedugt CL, Rahbe SM, Miller SD. Differential expression of inflammatory cytokines parallels progression of central nervous system pathology in two clinically distinct models of multiple sclerosis. J Immunol 1998; 161:4437-4446.
63. Liu JS, Zhao ML, Brosnan CF, Lee SC. Expression of inducible nitric oxide synthase and nitrotyrosine in multiple sclerosis lesions. Am J Pathol 2001; 158:2057-2066.
64. Kawahara K, Gotoh T, Oyadomari S, et al. Co-induction of argininosuccinate synthetase, cationic amino acid transporter-2, and nitric oxide synthase in activated murine microglial cells. Brain Res Mol Brain Res 2001; 90:165-173.
65. Nomura Y. NF-kappaB activation and IkappaB alpha dynamism involved in iNOS and chemokine induction in astroglial cells. Life Sci 2001; 68:1695-1701.
66. Anderson DW, Ellenberg JH, Leventhal CM, et al. Revised estimate of the prevalence of multiple sclerosis in the United States. Ann Neurol 1992; 31:333-336.
67. Duda PW, Schmied MC, Cook SL, et al. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest 2000; 105:967-976.
68. Stüve O, Dooley NP, Uhm JH, et al. Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol 1996; 40:853-863.
69. Leppert D, Waubant E, Burk MR, et al. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol 1996; 40:846-852.
70. Stüve O, Chabot S, Jung SS, et al. Chemokine-enhanced migration of human peripheral blood mononuclear cells is antagonized by interferon beta-1b through an effect on matrix metalloproteinase-9. J Neuroimmunol 1997; 80:38-46.
71. Cummings JL, Cole G. Alzheimer disease. JAMA 2002; 287:2335-2338.
72. Kang J, Lemaire HG, Unterbeck A, et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987; 325:733-736.
73. Haass C, Schlossmacher MG, Hung AY, et al. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 1992; 359:322-325.
74. Li QX, Whyte S, Tanner JE, et al. Secretion of Alzheimer's disease Abeta amyloid peptide by activated human platelets. Lab Invest 1998; 78:461-469.
75. Jick H, Zornberg GL, Jick SS, et al. Statins and the risk of dementia. Lancet 2000; 356:1627-1631. This was one of the first reports to suggest a beneficial clinical effect of statins on dementia
76. Rockwood K, Kirkland S, Hogan DB, et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 2002; 59:223-227.
77. Fassbender K, Stroick M, Bertsch T, et al. Effects of statins on human cerebral cholesterol metabolism and secretion of Alzheimer amyloid peptide. Neurology 2002; 59:1257-1258.
78. Locatelli S, Lutjohann D, Schmidt HH, et al. Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia: evidence that simvastatin affects cholesterol metabolism in the human brain. Arch Neurol 2002; 59:213-216.
79. Simons M, Schwarzler F, Lutjohann D, et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol 2002; 52:346-350.
80. Fassbender K, Simons M, Bergmann C, et al. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci U S A 2001; 98:5856-5861.
81. Yankner BA, Dawes LR, Fisher S, et al. Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. Science 1989; 245:417-420.
82. Thomas T, Thomas G, McLendon C, et al. beta-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature 1996; 380:168-171.
83. Xu J, Chen S, Ahmed SH, et al. Amyloid-beta peptides are cytotoxic to oligodendrocytes. J Neurosci 2001; 21:RC118.
84. Mirzabekov TA, Lin MC, Kagan BL. Pore formation by the cytotoxic islet amyloid peptide amylin. J Biol Chem 1996; 271:1988-1992.
85. Holscher C. Possible causes of Alzheimer's disease: amyloid fragments, free radicals, and calcium homeostasis. Neurobiol Dis 1998; 5:129-141.
86. Yang AJ, Chandswangbhuvana D, Margol L, Glabe CG. Loss of endosomal/lysosomal membrane impermeability is an early event in amyloid Abeta1-42 pathogenesis. J Neurosci Res 1998; 52:691-698.
87. World Health Organization. World Health Report 1999 - Making a Difference. Geneva, Switzerland: World Health Organization; 1999.
88. Ridker PM. Inflammatory biomarkers, statins, and the risk of stroke: cracking a clinical conundrum. Circulation 2002; 105:2583-2585.
89. Atkins D, Psaty BM, Koepsell TD, et al. Cholesterol reduction and the risk for stroke in men. A meta-analysis of randomized, controlled trials. Ann Intern Med 1993; 119:136-145.
90. Hebert PR, Gaziano JM, Hennekens CH. An overview of trials of cholesterol lowering and risk of stroke. Arch Intern Med 1995; 155:50-55.
91. Pedersen TR, Kjekshus J, Pyorala K, et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). Am J Cardiol 1998; 81:333-335.
92. White HD, Simes PJ, Anderson NE, et al. Pravastatin therapy and the risk of stroke. N Engl J Med 2000; 343:317-326.
93. Byington RP, Davis BR, Plehn JF, et al. Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation 2001; 103:387-392.
94. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340:115-126.
95. Barone FC, Feuerstein GZ. Inflammatory mediators and stroke: new opportunities for novel therapeutics. J Cereb Blood Flow Metab 1999; 19:819-834.
96. Engstrom G, Lind P, Hedblad B, et al. Effects of cholesterol and inflammation-sensitive plasma proteins on incidence of myocardial infarction and stroke in men. Circulation 2002; 105:2632-2637. This article presents further evidence for inflammation as a risk factor for ischemic stroke
97. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336:973-979.
98. Rost NS, Wolf PA, Kase CS, et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke 2001; 32:2575-2579.
99. Becker KJ, McCarron RM, Ruetzler et al. Immunologic toferance to myelin basic protein decreases stroke size after transient focal cerebral ischemia. Proc Natl Acad Sci U S A 1997; 94:10873-10878.